173 related articles for article (PubMed ID: 27900369)
1. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.
Biswas R; Gao S; Cultraro CM; Maity TK; Venugopalan A; Abdullaev Z; Shaytan AK; Carter CA; Thomas A; Rajan A; Song Y; Pitts S; Chen K; Bass S; Boland J; Hanada KI; Chen J; Meltzer PS; Panchenko AR; Yang JC; Pack S; Giaccone G; Schrump DS; Khan J; Guha U
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001263. PubMed ID: 27900369
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Zhang X; Nguyen KD; Rudnick PA; Roper N; Kawaler E; Maity TK; Awasthi S; Gao S; Biswas R; Venugopalan A; Cultraro CM; Fenyö D; Guha U
Mol Cell Proteomics; 2019 Apr; 18(4):622-641. PubMed ID: 30617155
[TBL] [Abstract][Full Text] [Related]
3. Genomic Alteration During Metastasis of Lung Adenocarcinoma.
Tan Q; Cui J; Huang J; Ding Z; Lin H; Niu X; Li Z; Wang G; Luo Q; Lu S
Cell Physiol Biochem; 2016; 38(2):469-86. PubMed ID: 26828653
[TBL] [Abstract][Full Text] [Related]
4. Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma.
Lee HW; Park YM; Lee SJ; Cho HJ; Kim DH; Lee JI; Kang MS; Seol HJ; Shim YM; Nam DH; Kim HH; Joo KM
Clin Cancer Res; 2013 Nov; 19(21):5879-89. PubMed ID: 23995859
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract][Full Text] [Related]
6. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
7. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
9. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
10. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J
J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of ERBB2 gene overexpression by the formation of super-enhancer with genomic structural abnormalities in lung adenocarcinoma without clinically actionable genetic alterations.
Kaneko S; Takasawa K; Asada K; Shiraishi K; Ikawa N; Machino H; Shinkai N; Matsuda M; Masuda M; Adachi S; Takahashi S; Kobayashi K; Kouno N; Bolatkan A; Komatsu M; Yamada M; Miyake M; Watanabe H; Tateishi A; Mizuno T; Okubo Y; Mukai M; Yoshida T; Yoshida Y; Horinouchi H; Watanabe SI; Ohe Y; Yatabe Y; Saloura V; Kohno T; Hamamoto R
Mol Cancer; 2024 Jun; 23(1):126. PubMed ID: 38862995
[TBL] [Abstract][Full Text] [Related]
12. Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Kim EY; Cho EN; Park HS; Kim A; Hong JY; Lim S; Youn JP; Hwang SY; Chang YS
BMC Cancer; 2016 Jan; 16():27. PubMed ID: 26782967
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
14. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
15. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang JC; Stehr H; Liang Y; Das M; Huang J; Diehn M; Wakelee HA; Neal JW
J Thorac Oncol; 2017 May; 12(5):833-842. PubMed ID: 28167203
[TBL] [Abstract][Full Text] [Related]
16. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
[TBL] [Abstract][Full Text] [Related]
17. ERBB2 kinase domain mutation in a gastric cancer metastasis.
Lee JW; Soung YH; Kim SY; Park WS; Nam SW; Kim SH; Lee JY; Yoo NJ; Lee SH
APMIS; 2005 Oct; 113(10):683-7. PubMed ID: 16309427
[TBL] [Abstract][Full Text] [Related]
18. Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma.
Chen YC; Lin MC; Hsiao CC; Zheng YX; Chen KD; Sung MT; Chen CJ; Wang TY; Lin YY; Chang HC; Chen YM; Chang JC
Oncotarget; 2017 Jul; 8(28):45710-45724. PubMed ID: 28498804
[TBL] [Abstract][Full Text] [Related]
19. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
20. Genomic alterations in lung adenocarcinoma.
Devarakonda S; Morgensztern D; Govindan R
Lancet Oncol; 2015 Jul; 16(7):e342-51. PubMed ID: 26149886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
